Statistically significant improvements in HAQ-DI scores were observed in patients treated with RoActemra compared with patients treated with DMARDs.
RoActemra’ ga ravitud patsientidel täheldati HAQ- DI skoori statistiliselt olulist paranemist võrreldes DMARDe saanud patsientidega.